H.C. Wainwright initiated coverage of Jade Biosciences (JBIO) with a Buy rating and $25 price target The firm believes the company is a well positioned to become a leader in the autoimmune space. It projects risk-adjusted revenues to reach $926M by 2037 based on JADE101 in immunoglobulin A nephropathy alone.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JBIO:
- Jade Biosciences Outlines 2026 Autoimmune Pipeline Priorities
- Jade Biosciences outlines key 2026 objectives, strategy
- Jade Biosciences files to sell 3.21M shares of common stock for holders
- Jade Biosciences Announces Private Placement Agreement
- Jade Biosciences prices 3.21M shares at $14.00 in private placement